Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast...

Area of Science:

• Oncology
• Breast Cancer Research
• Real-World Evidence Studies

Background:

• Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype with limited survival data.
• Comprehensive real-world evidence for locally recurrent and mTNBC is lacking.
• Integrating real-world data with clinical trials is crucial for optimizing mTNBC treatment.

Purpose of the Study:

• To analyze treatment patterns and outcomes in advanced triple-negative breast cancer (TNBC) patients.
• To leverage nationwide real-world data from all Danish oncology sites.
• To provide insights into the management of metastatic and recurrent TNBC.

Main Methods:

• Retrospective, non-interventional, population-based observational study.
• Inclusion of all women diagnosed with metastatic or locally recurrent TNBC (2017-2019).
• Analysis of overall survival (OS) and progression-free survival (PFS) across treatment lines using the Danish Breast Cancer Group database.

Main Results:

• The study included 243 women with metastatic or recurrent TNBC.
• Median overall survival (mOS) was 11.6 months (first line), 6.5 months (second line), and 6.5 months (third line).
• De novo mTNBC and relapse within 18 months were associated with significantly shorter OS.

Conclusions:

• Nationwide real-world data indicates poor OS for metastatic or recurrent TNBC patients (mOS: 11.6 months).
• Early relapse or de novo metastatic disease negatively impacts patient survival.
• Treatment preferences varied: taxanes for de novo mTNBC, capecitabine for recurrent TNBC.